GlassScriptPhysician profile
Mindy Raminick
NPI 1306292438
$3,024.56
in general payments reported to CMS, 2019-2025
27 companies · $97.40 in 2025
The $97.40 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $743 · 2021: $262 · 2022: $77.87 · 2023: $195 · 2024: $783 · 2025: $97.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $925 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $925.16 |
| Education | $149.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $354.25 | 2019-2021 | |
| Vifor Pharma, INC. | $309.96 | 2019-2023 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $245.07 | 2019-2024 | Jynarque |
| Amgen INC. | $208.20 | 2021-2025 | Tavneos, Krystexxa |
| Aurinia Pharma U.S., INC. | $197.73 | 2023-2024 | Lupkynis |
| Fresenius USA Marketing, INC. | $190.82 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $173.70 | 2019-2024 | Soliris |
| Mallinckrodt Hospital Products INC. | $167.82 | 2020-2021 | |
| Novo Nordisk INC | $143.09 | 2024 | Wegovy |
| Genzyme Corporation | $138.28 | 2020 | |
| Janssen Scientific Affairs, LLC | $123.98 | 2019 | |
| Mallinckrodt Enterprises LLC | $117.18 | 2019 | |
| Opko Pharmaceuticals, LLC | $107.94 | 2019-2021 | |
| Lundbeck LLC | $89.42 | 2019 | |
| Akebia Therapeutics INC | $67.91 | 2021-2024 | Auryxia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $62.03 | 2024-2025 | |
| Travere Therapeutics, INC. | $51.87 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.09 | 2024 | Jardiance |
| Calliditas Therapeutics US INC. | $43.83 | 2022-2024 | |
| Ardelyx, INC. | $35.52 | 2024-2025 | Ibsrela |
| Daiichi Sankyo INC. | $31.49 | 2023-2024 | Injectafer |
| Glaxosmithkline, LLC. | $26.03 | 2022 | |
| Recor Medical INC | $23.43 | 2024 | Paradise Renal Denervation System |
| Nxstage Medical, INC. | $21.99 | 2020 | |
| Scpharmaceuticals INC. | $20.29 | 2025 | |
| Bardy Diagnostics, INC. | $14.55 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.09 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mindy Raminick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.